CPT code 64681 denotes neurolytic destruction of the superior hypogastric plexus to reduce pelvic pain, often used for malignant pain or refractory pelvic pain from conditions such as endometriosis. The procedure can employ chemical, thermal, or electrical means and is commonly performed with imaging guidance. Nationally, this code is relevant for specialty pain practices, interventional radiology, and oncology palliative care due to its role in managing severe pelvic pain when conservative measures fail.

Key payers in coverage discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers can expect coverage and utilization benchmarks, common clinical indications, and coding context relevant to billing and prior authorization workflows. The publication provides guidance on typical service settings, expected documentation elements tied to indication and imaging guidance, and how payers commonly frame medical necessity for neurolytic procedures.

This summary is intended for a national audience of clinicians, practice managers, and reimbursement analysts seeking a concise overview of CPT code 64681, its clinical application, and the payer landscape. Data not available in the input is noted where applicable in detailed sections.